FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2994325013> ?p ?o ?g. }

• W2994325013 abstract "Abstract Background Endocrine therapies are still the main strategy for the treatment of oestrogen receptor-positive (ER+) breast cancers (BC), but resistance remains problematic. Cross-talk between ER and PI3K/AKT/mTORC has been associated with ligand-independent transcription of ER. We have previously reported the anti-proliferative effects of the combination of everolimus (an mTORC1 inhibitor) with endocrine therapy in resistance models, but potential routes of escape via AKT signalling can lead to resistance; therefore, the use of dual mTORC1/2 inhibitors has met with significant interest. Methods To address this, we tested the effect of vistusertib, a dual mTORC1 and mTORC2 inhibitor, in a panel of endocrine-resistant and endocrine-sensitive ER+ BC cell lines, with varying PTEN , PIK3CA and ESR1 mutation status. End-points included proliferation, cell signalling, cell cycle and effect on ER-mediated transcription. Two patient-derived xenografts (PDX) modelling endocrine resistance were used to assess the efficacy of vistusertib, fulvestrant or the combination on tumour progression, and biomarker studies were conducted using immunohistochemistry and RNA-seq technologies. Results Vistusertib caused a dose-dependent decrease in proliferation of all the cell lines tested and reduced abundance of mTORC1, mTORC2 and cell cycle markers, but caused an increase in abundance of EGFR, IGF1R and ERBB3 in a context-dependent manner. ER-mediated transcription showed minimal effect of vistusertib. Combined therapy of vistusertib with fulvestrant showed synergy in two ER+ PDX models of resistance to endocrine therapy and delayed tumour progression after cessation of therapy. Conclusions These data support the notion that models of acquired endocrine resistance may have a different sensitivity to mTOR inhibitor/endocrine therapy combinations." @default.
• W2994325013 created "2019-12-13" @default.
• W2994325013 creator A5001140222 @default.
• W2994325013 creator A5008958472 @default.
• W2994325013 creator A5010370253 @default.
• W2994325013 creator A5013730565 @default.
• W2994325013 creator A5023779153 @default.
• W2994325013 creator A5030561107 @default.
• W2994325013 creator A5031915637 @default.
• W2994325013 creator A5032209796 @default.
• W2994325013 creator A5057689412 @default.
• W2994325013 creator A5064188148 @default.
• W2994325013 creator A5064358450 @default.
• W2994325013 creator A5068603135 @default.
• W2994325013 creator A5075105162 @default.
• W2994325013 creator A5079758317 @default.
• W2994325013 creator A5091210130 @default.
• W2994325013 date "2019-12-01" @default.
• W2994325013 modified "2023-10-17" @default.
• W2994325013 title "Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer" @default.
• W2994325013 cites W1464936406 @default.
• W2994325013 cites W1873528488 @default.
• W2994325013 cites W1913159188 @default.
• W2994325013 cites W1967639975 @default.
• W2994325013 cites W1992533338 @default.
• W2994325013 cites W1998162919 @default.
• W2994325013 cites W2026595973 @default.
• W2994325013 cites W2031131661 @default.
• W2994325013 cites W2077945404 @default.
• W2994325013 cites W2088158153 @default.
• W2994325013 cites W2100980757 @default.
• W2994325013 cites W2111945133 @default.
• W2994325013 cites W2114104545 @default.
• W2994325013 cites W2116013203 @default.
• W2994325013 cites W2134526812 @default.
• W2994325013 cites W2143439281 @default.
• W2994325013 cites W2167188058 @default.
• W2994325013 cites W2169456326 @default.
• W2994325013 cites W2169988894 @default.
• W2994325013 cites W2299045691 @default.
• W2994325013 cites W2309969893 @default.
• W2994325013 cites W2552099557 @default.
• W2994325013 cites W2594046947 @default.
• W2994325013 cites W2601176113 @default.
• W2994325013 cites W2765643657 @default.
• W2994325013 cites W2790152406 @default.
• W2994325013 cites W2790833436 @default.
• W2994325013 cites W2806419697 @default.
• W2994325013 cites W2955160320 @default.
• W2994325013 cites W4241774195 @default.
• W2994325013 doi "https://doi.org/10.1186/s13058-019-1222-0" @default.
• W2994325013 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6993431" @default.
• W2994325013 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32005287" @default.
• W2994325013 hasPublicationYear "2019" @default.
• W2994325013 type Work @default.
• W2994325013 sameAs 2994325013 @default.
• W2994325013 citedByCount "11" @default.
• W2994325013 countsByYear W29943250132020 @default.
• W2994325013 countsByYear W29943250132021 @default.
• W2994325013 countsByYear W29943250132022 @default.
• W2994325013 countsByYear W29943250132023 @default.
• W2994325013 crossrefType "journal-article" @default.
• W2994325013 hasAuthorship W2994325013A5001140222 @default.
• W2994325013 hasAuthorship W2994325013A5008958472 @default.
• W2994325013 hasAuthorship W2994325013A5010370253 @default.
• W2994325013 hasAuthorship W2994325013A5013730565 @default.
• W2994325013 hasAuthorship W2994325013A5023779153 @default.
• W2994325013 hasAuthorship W2994325013A5030561107 @default.
• W2994325013 hasAuthorship W2994325013A5031915637 @default.
• W2994325013 hasAuthorship W2994325013A5032209796 @default.
• W2994325013 hasAuthorship W2994325013A5057689412 @default.
• W2994325013 hasAuthorship W2994325013A5064188148 @default.
• W2994325013 hasAuthorship W2994325013A5064358450 @default.
• W2994325013 hasAuthorship W2994325013A5068603135 @default.
• W2994325013 hasAuthorship W2994325013A5075105162 @default.
• W2994325013 hasAuthorship W2994325013A5079758317 @default.
• W2994325013 hasAuthorship W2994325013A5091210130 @default.
• W2994325013 hasBestOaLocation W29943250131 @default.
• W2994325013 hasConcept C121608353 @default.
• W2994325013 hasConcept C126322002 @default.
• W2994325013 hasConcept C134018914 @default.
• W2994325013 hasConcept C143998085 @default.
• W2994325013 hasConcept C151730666 @default.
• W2994325013 hasConcept C2777609662 @default.
• W2994325013 hasConcept C2779343474 @default.
• W2994325013 hasConcept C2779699572 @default.
• W2994325013 hasConcept C2780482068 @default.
• W2994325013 hasConcept C2781230642 @default.
• W2994325013 hasConcept C502942594 @default.
• W2994325013 hasConcept C530470458 @default.
• W2994325013 hasConcept C62478195 @default.
• W2994325013 hasConcept C71924100 @default.
• W2994325013 hasConcept C84606932 @default.
• W2994325013 hasConcept C86554907 @default.
• W2994325013 hasConcept C86803240 @default.
• W2994325013 hasConcept C95444343 @default.
• W2994325013 hasConcept C98490376 @default.
• W2994325013 hasConceptScore W2994325013C121608353 @default.
• W2994325013 hasConceptScore W2994325013C126322002 @default.
• W2994325013 hasConceptScore W2994325013C134018914 @default.

• next